Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.
Press releases published on May 31, 2025
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Krispy Kreme, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DNUT
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Krispy Kreme, Inc. (NASDAQ: DNUT) between February 25, 2025 and May 7, 2025, both dates inclusive (the “Class Period”), …
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eagle Bancorp, Inc. Investors to Inquire About Securities Class Action Investigation – EGBN
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Eagle Bancorp, Inc. (NASDAQ: EGBN) resulting from allegations that Eagle …
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 31, 2025
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal …
GoHealth, Inc. Investor News: If You Have Suffered Losses in GoHealth, Inc. (NASDAQ: GOCO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GoHealth, Inc. (NASDAQ: GOCO) resulting from allegations that GoHealth may …
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVDX, TASK, BRDG on Behalf of Shareholders
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: …
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BSGM, SGN, HLGN on Behalf of Shareholders
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: …
TMCI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period …
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAR
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class …
CGC IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Canopy Growth Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CGC
GlobeNewswire
·
May 31, 2025
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class …
Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
GlobeNewswire
·
May 31, 2025
New York City, NY, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction In the crowded world of online trading platforms, separating legitimate services from elaborate scams can be a daunting task. Trade 350 App has emerged as one of the buzziest names in 2025, …
Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
GlobeNewswire
·
May 31, 2025
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the Starscope Monocular Is Gaining Popularity in 2025 Whether you're a nature lover, hiker, hunter, or stargazer, having the right optical gear can make or break your outdoor experience. In …
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
GlobeNewswire
·
May 31, 2025
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a UK-based cloud mining provider regulated by the Financial Conduct Authority (FCA), has announced a major expansion of its services. This strategic move comes amid a surge in global …
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
GlobeNewswire
·
May 31, 2025
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As Bitcoin prices rise past key resistance levels, investor interest in digital assets is once again on the upswing. PAIRMiner, a cloud-based cryptocurrency mining platform, is helping …
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
GlobeNewswire
·
May 31, 2025
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to …
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
GlobeNewswire
·
May 31, 2025
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
GlobeNewswire
·
May 31, 2025
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median …
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
GlobeNewswire
·
May 31, 2025
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1. L’analyse post-hoc de l’étude NAPOLI 3 a permis de déterminer …
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
GlobeNewswire
·
May 31, 2025
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years …
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
GlobeNewswire
·
May 31, 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
GlobeNewswire
·
May 31, 2025
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated incidence and mortality in a high-risk population Data …